AVI BioPharma, Inc. Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease

PORTLAND, Ore.--(BUSINESS WIRE)--AVI BioPharma, Inc. (Nasdaq:AVII) announced today that its partner Cook Medical has completed target patient enrollment and released six-month follow-up data from a Phase II clinical trial known as APPRAISAL. The trial, currently being held in Germany, was designed to study the effect of the NEUGENE® antisense drug Resten-MP™, when used in conjunction with the placement of one or more bare metal stents, in the prevention of cardiovascular restenosis, the narrowing of an artery following a cardiac procedure such as angioplasty.